- Conference Call to Discuss Results to Be Held at 9:00 A.M. -
EXTON, Pa., Feb. 12 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (NASDAQ:VPHM) fourth quarter and year end financial results for 2007 and guidance for 2008 are expected to be released on Wednesday, February 27, 2008 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2007 fourth quarter and full year financial results and other business.
The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com/. An audio archive will be available at the same address until March 14, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com/. DATASOURCE: ViroPharma Incorporated CONTACT: William C. Roberts, Vice President, Corporate Communications, +1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications, +1-610-321-6290, both of ViroPharma Incorporated Web site: http://www.viropharma.com/
|